Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $17.36, but opened at $16.72. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $16.78, with a volume of 3,158 shares changing hands.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Wednesday, March 12th. Wedbush assumed coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research report on Thursday. They issued an "outperform" rating and a $22.00 target price on the stock.
Get Our Latest Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
The company has a 50 day moving average price of $16.76 and a two-hundred day moving average price of $16.87.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Stories
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
